» Authors » Eric Francois

Eric Francois

Explore the profile of Eric Francois including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 113
Citations 4738
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrier M, Fontaine M, Bertin E, Carlier C, Botsen D, Djelouah M, et al.
Eur J Clin Nutr . 2025 Feb; PMID: 39910182
Background: Low skeletal muscle mass and impaired muscle quality (myosteatosis) have been associated with poor outcomes in cancer patients. This study aimed to evaluate the impact of pre-therapeutic low muscle...
2.
Boisteau E, Dahan L, Williet N, Le Malicot K, Desrame J, Bouche O, et al.
Oncologist . 2024 Sep; 29(9):e1149-e1158. PMID: 39235326
Introduction: Predictive markers of LV5FU2 maintenance benefit after first-line induction with FOLFIRINOX in patients with metastatic pancreatic cancer are necessary to select patients who will not be harmed by this...
3.
Francois E, Magne N, Boulahssass R, Ronchin P, Huguenet V, De Lavigerie B, et al.
Radiother Oncol . 2024 Feb; 193:110144. PMID: 38341097
Background: The results of the PRODIGE 42/GERICO 12 study showed that short course radiotherapy had a better tolerance profile than radiochemotherapy, with comparable oncological results. We have included Quality of...
4.
Verma A, Francois E, Maiti T, Cassidy L, Tolba R
Pain Pract . 2023 Dec; 24(3):567-572. PMID: 38050874
Background: Post herpetic neuralgia (PHN) is a chronic neuropathic pain syndrome which presents after an episode of herpes zoster caused by the reactivation of varicella zoster virus. Conservative treatment starts...
5.
Nicolle R, Bachet J, Harle A, Iovanna J, Hammel P, Rebours V, et al.
J Clin Oncol . 2023 Nov; 42(9):1067-1076. PMID: 37963313
Purpose: GemPred, a transcriptomic signature predictive of the efficacy of adjuvant gemcitabine (GEM), was developed from cell lines and organoids and validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has...
6.
Boige V, Blons H, Francois E, Abdelghani M, Phelip J, Le Brun-Ly V, et al.
JAMA Netw Open . 2023 Sep; 6(9):e2333533. PMID: 37721754
Importance: The optimal maintenance strategy after induction chemotherapy with anti-epidermal growth factor receptor antibody for patients with RAS wild-type metastatic colorectal cancer (mCRC) remains to be debated. Objective: To evaluate...
7.
Bailleux C, Zwarthoed C, Evesque L, Baron D, Scouarnec C, Benezery K, et al.
Radiother Oncol . 2023 Sep; 188:109905. PMID: 37678620
Background And Purpose: The aim of our prospective study was to assess the prognostic value of 18F-FDG PET/CT performed two months post treatment for anal canal neoplasm. Population And Methods:...
8.
Kim S, Vendrely V, Saint A, Andre T, Vaflard P, Samalin E, et al.
Exp Hematol Oncol . 2023 Jul; 12(1):63. PMID: 37480095
Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard treatments....
9.
de Rauglaudre B, Sibertin-Blanc C, Fabre A, Le Malicot K, Bennouna J, Ghiringhelli F, et al.
Ther Adv Med Oncol . 2023 Jan; 14:17588359221141307. PMID: 36601631
Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor () pathway genes on the efficacy of bevacizumab in metastatic colorectal cancer (mCRC),...
10.
Francois E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, et al.
Eur J Cancer . 2022 Dec; 180:62-70. PMID: 36535196
Background: There is no specific guideline for the treatment of locally advanced rectal cancers in the elderly. Here we compared R0 resection rate and degradation of autonomy based on the...